What should I avoid while taking Cenobamate 200mg tablets?

Avoid alcohol. Alcohol may increase somnolence and sedation. Take with or without food. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Cenobamate 200mg tablets?

Cenobamate 200mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Cenobamate 200mg tablets?

Cenobamate 200mg tablets is the generic name. It is available under brand names including: Ontozry 200mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Cenobamate 200mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

200mg

Oral

Antiepileptic

Antiepileptic drugs

Active ingredients:

Cenobamate

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.08.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N03AX25

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Antiepileptic

Check interactions for Cenobamate

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Cenobamate

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Cenobamate

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Cenobamate

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Cenobamate on the MHRA register

Ontozry 200mg tablets

Angelini Pharma UK-I Ltd

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£91.00indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

200 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Zonisamide 200mg capsules

Capsule

200mg

Same therapeutic group

Sultiame 20mg/ml oral suspension

Oral suspension

20mg

Same therapeutic group

Zonisamide 20mg/ml oral suspension sugar free

Oral suspension

20mg

Same therapeutic group

Topiramate 20mg/ml oral solution sugar free

Oral solution

20mg

Same therapeutic group

Lamotrigine 10mg/ml oral suspension sugar free

Oral suspension

10mg

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Cenobamate

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(2)

Cenobamate for treating focal onset seizures in epilepsy (TA753)

TA753

Technology appraisal

Updated Jul 2025

Epilepsies in children, young people and adults (NG217)

NG217

NICE guideline

Updated Jan 2025

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Cenobamate

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

40206611000001107

dm+d ID

40206611000001107

VTM (Virtual Therapeutic Moiety)

830245002

VMP (Virtual Medicinal Product)

40206611000001107

BNF code

04080100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N03AX25

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

50-60h

Mechanism

Cenobamate inhibits voltage gated sodium channels and is a positive GABAA modulator.

Food interactions

2 warnings

Human targets

2 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

88%

Cenobamate is 88% orally bioavailable with a T_max of 1-4 hours.
[L10653]…

Half-life

50-60h

The terminal half life of cenobamate is 50-60h.
[L10653]

Protein binding

60%

Cenobamate is 60% protein bound in plasma, mainly serum albumin.
[L10653]

Volume of distribution

40-50L

The apparent volume of distribution of cenobamate is 40-50L.
[L10653]

Metabolism

Data regarding the metabolism of cenobamate is lacking, however it is mostly glucuronidated by UGT2B7 and UGT2B4 or oxidized by a number of cytochromes.
[L10653]…

Elimination

87.8%

Cenobamate is 87.8% eliminated in the urine and 5.2% in the feces.
[L10653]

Clearance

0.45-0.63L/h

The apparent oral clearance of cenobamate is 0.45-0.63L/h for a 100-400mg/day dose.
[L10653]

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.[A188442][L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABA_A and inhibits voltage gated sodium channels.[L10653]

Cenobamate was granted FDA approval on 21 November 2019.[L10653]

Properties:

solid

Avg. mass: 267.67 Da

DrugBank indication

Cenobamate is indicated for the treatment of partial onset seizures in adults.
[L10653]

Also known as(126)

Cenobamate

Cénobamate

Cenobamato

Cenobamatum

NAC1

SCN1

Sodium channel protein brain I subunit alpha

Sodium channel protein type I subunit alpha

Dosage forms(25)

(Oral) — 25 + 12.5 mg

Tablet, film coated (Oral) — 100 MG

Tablet, film coated (Oral) — 150 MG

Tablet, film coated (Oral) — 200 MG

Tablet, film coated (Oral) — 50 MG

Kit; tablet (Oral)

Tablet (Oral) — 100 mg

Tablet (Oral) — 12.5 mg

Molecular properties(19)

Drug interactions(1153)

Known interactions with other medications. Always consult a healthcare professional.

Dabrafenib

Unknown severity

DB08912

The serum concentration of Cenobamate can be decreased when it is combined with Dabrafenib.

Check this interaction

Eliglustat

Moderate

DB09039

The metabolism of Eliglustat can be decreased when combined with Cenobamate.

Check this interaction

Ibrutinib

Moderate

DB09053

The metabolism of Ibrutinib can be decreased when combined with Cenobamate.

Check this interaction

Luliconazole

Unknown severity

DB08933

The serum concentration of Cenobamate can be increased when it is combined with Luliconazole.

Check this interaction

Cilostazol

Unknown severity

DB01166

The serum concentration of Cilostazol can be increased when it is combined with Cenobamate.

Check this interaction

Colchicine

Moderate

DB01394

The metabolism of Colchicine can be decreased when combined with Cenobamate.

Check this interaction

Fentanyl

Unknown severity

DB00813

The serum concentration of Fentanyl can be decreased when it is combined with Cenobamate.

Check this interaction

Iloperidone

Moderate

DB04946

The metabolism of Iloperidone can be decreased when combined with Cenobamate.

Check this interaction

Retapamulin

Moderate

DB01256

The metabolism of Retapamulin can be decreased when combined with Cenobamate.

Check this interaction

Tofacitinib

Moderate

DB08895

The metabolism of Tofacitinib can be decreased when combined with Cenobamate.

Check this interaction

Vardenafil

Moderate

DB00862

The metabolism of Vardenafil can be decreased when combined with Cenobamate.

Check this interaction

Lovastatin

Moderate

DB00227

The metabolism of Lovastatin can be decreased when combined with Cenobamate.

Check this interaction

Mefloquine

Moderate

DB00358

The therapeutic efficacy of Cenobamate can be decreased when used in combination with Mefloquine.

Check this interaction

Mianserin

Moderate

DB06148

The therapeutic efficacy of Cenobamate can be decreased when used in combination with Mianserin.

Check this interaction

Orlistat

Moderate

DB01083

Orlistat can cause a decrease in the absorption of Cenobamate resulting in a reduced serum concentration and potentially a decrease in efficacy.

Check this interaction

Topotecan

Moderate

DB01030

Cenobamate may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Alfuzosin

Moderate

DB00346

The metabolism of Alfuzosin can be decreased when combined with Cenobamate.

Check this interaction

Alprazolam

Moderate

DB00404

The metabolism of Alprazolam can be decreased when combined with Cenobamate.

Check this interaction

Ifosfamide

Moderate

DB01181

The metabolism of Ifosfamide can be increased when combined with Cenobamate.

Check this interaction

Perampanel

Moderate

DB08883

The metabolism of Perampanel can be increased when combined with Cenobamate.

Check this interaction

R,S-Warfarin alcohol

Unknown severity

DB08735

The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Cenobamate.

Check this interaction

S,R-Warfarin alcohol

Unknown severity

DB08736

The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Cenobamate.

Check this interaction

Midazolam

Unknown severity

DB00683

The serum concentration of Midazolam can be increased when it is combined with Cenobamate.

Check this interaction

Tetracosactide

Unknown severity

DB01284

The risk or severity of liver damage can be increased when Tetracosactide is combined with Cenobamate.

Check this interaction

Tacrolimus

Unknown severity

DB00864

The serum concentration of Tacrolimus can be increased when it is combined with Cenobamate.

Check this interaction

Atorvastatin

Moderate

DB01076

The metabolism of Atorvastatin can be decreased when combined with Cenobamate.

Check this interaction

Lumacaftor

Unknown severity

DB09280

The serum concentration of Cenobamate can be decreased when it is combined with Lumacaftor.

Check this interaction

Erlotinib

Unknown severity

DB00530

The serum concentration of Erlotinib can be decreased when it is combined with Cenobamate.

Check this interaction

Chloramphenicol

Moderate

DB00446

The metabolism of Cenobamate can be decreased when combined with Chloramphenicol.

Check this interaction

Isoniazid

Moderate

DB00951

The metabolism of Cenobamate can be decreased when combined with Isoniazid.

Check this interaction

Miconazole

Moderate

DB01110

The metabolism of Cenobamate can be decreased when combined with Miconazole.

Check this interaction

Zafirlukast

Moderate

DB00549

The metabolism of Cenobamate can be decreased when combined with Zafirlukast.

Check this interaction

Eslicarbazepine acetate

Moderate

DB09119

The metabolism of Cenobamate can be decreased when combined with Eslicarbazepine acetate.

Check this interaction

Tranylcypromine

Moderate

DB00752

The metabolism of Cenobamate can be decreased when combined with Tranylcypromine.

Check this interaction

Caffeine

Moderate

DB00201

Cenobamate may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Dyphylline

Moderate

DB00651

Cenobamate may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Pentoxifylline

Moderate

DB00806

Cenobamate may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Mercaptopurine

Moderate

DB01033

Cenobamate may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Oxtriphylline

Moderate

DB01303

Cenobamate may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Theobromine

Moderate

DB01412

Cenobamate may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Fenethylline

Moderate

DB01482

Cenobamate may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

8-azaguanine

Moderate

DB01667

Cenobamate may increase the excretion rate of 8-azaguanine which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

7,9-Dimethylguanine

Moderate

DB01978

Cenobamate may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Xanthine

Moderate

DB02134

Cenobamate may increase the excretion rate of Xanthine which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

7-Deazaguanine

Moderate

DB02245

Cenobamate may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Guanine

Moderate

DB02377

Cenobamate may increase the excretion rate of Guanine which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

9-Methylguanine

Moderate

DB02489

Cenobamate may increase the excretion rate of 9-Methylguanine which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Peldesine

Moderate

DB02568

Cenobamate may increase the excretion rate of Peldesine which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Hypoxanthine

Moderate

DB04076

Cenobamate may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

9-Deazaguanine

Moderate

DB04356

Cenobamate may increase the excretion rate of 9-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.

Check this interaction

Showing 50 of 1153 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol. Alcohol may increase somnolence and sedation.

Advice

Take with or without food.

Toxicity & overdose

There is limited information regarding the signs, symptoms, and treatment of a cenobamate overdose.
[L10653]
Symptomatic and supportive treatment is recommended and there is limited data on the utility of dialysis to remove cenobamate from blood.
[L10653]

How it works

Mechanism of action

Cenobamate inhibits voltage gated sodium channels and is a positive GABA_A modulator.[L10653] However, the exact mechanism of action remains unknown.[L10653] Inhibition of voltage gated sodium channels increases the threshold for generating action potentials and decreases the number of action potentials.[A188442]

Pharmacodynamics

The mechanism of cenobamate is unknown, however it modulates GABA_A and inhibit voltage gated sodium channels.[L10653] Cenobamate is given once daily and so it has a long duration of action.[L10653] The therapeutic window is wide as doses of 750mg can be well tolerated.[A188478] Patients should be counselled regarding the risk of DRESS syndrome, QT interval shortening, suicidal behavior, and neurological adverse effects.[L10653]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Cenobamate is 88% orally bioavailable with a T_max of 1-4 hours.
[L10653]
A high fat meal does not significantly impact the pharmacokinetics of cenobamate.
[L10653]

Plasma C_max and AUC for cenobamate crushed tablets mixed in water, administered either orally or through a nasogastric tube, were similar to whole tablets. The median T_max for crushed tablets is 0.5 hours.
[L51043]

Half-life

The terminal half life of cenobamate is 50-60h.
[L10653]

Protein binding

Cenobamate is 60% protein bound in plasma, mainly serum albumin.
[L10653]

Volume of distribution

The apparent volume of distribution of cenobamate is 40-50L.
[L10653]

Metabolism

Data regarding the metabolism of cenobamate is lacking, however it is mostly glucuronidated by UGT2B7 and UGT2B4 or oxidized by a number of cytochromes.
[L10653]

Route of elimination

Cenobamate is 87.8% eliminated in the urine and 5.2% in the feces.
[L10653]

Clearance

The apparent oral clearance of cenobamate is 0.45-0.63L/h for a 100-400mg/day dose.
[L10653]

Drug targets(2)

Proteins and enzymes this drug interacts with in the body

Sodium channel protein type 9 subunit alpha

BE0009738

SCN9A

inhibitor

Specific functionvoltage-gated sodium channel activity

Cellular location

Cell membrane

General function & pharmacology

Pore-forming subunit of Nav1.7, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient.

The influx of Na(+) ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues .
PMID:15385606 PMID:16988069 PMID:17145499 PMID:17167479 PMID:19369487 PMID:24311784 PMID:25240195 PMID:26680203 PMID:7720699

Nav1.7 plays a crucial role in controlling the excitability and action potential propagation from nociceptor neurons, thereby contributing to the sensory perception of pain PMID:17145499 PMID:17167479 PMID:19369487 PMID:24311784

Gamma-aminobutyric acid receptor subunit alpha-1

BE0000795

GABRA1

allosteric modulator

Specific functionGABA-A receptor activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Alpha subunit of the heteropentameric ligand-gated chloride channel gated by Gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain .
PMID:23909897 PMID:25489750 PMID:29950725 PMID:30602789

GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) .
PMID:29950725 PMID:30602789
When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient .
PMID:23909897 PMID:29950725 PMID:30602789

Alpha-1/GABRA1-containing GABAARs are largely synaptic (By similarity). Chloride influx into the postsynaptic neuron following GABAAR opening decreases the neuron ability to generate a new action potential, thereby reducing nerve transmission (By similarity). GABAARs containing alpha-1 and beta-2 or -3 subunits exhibit synaptogenic activity; the gamma-2 subunit being necessary but not sufficient to induce rapid synaptic contacts formation .
PMID:23909897 PMID:25489750
GABAARs function also as histamine receptor where histamine binds at the interface of two neighboring beta subunits and potentiates GABA response (By similarity).

GABAARs containing alpha, beta and epsilon subunits also permit spontaneous chloride channel activity while preserving the structural information required for GABA-gated openings (By similarity). Alpha-1-mediated plasticity in the orbitofrontal cortex regulates context-dependent action selection (By similarity). Together with rho subunits, may also control neuronal and glial GABAergic transmission in the cerebellum (By similarity)

Metabolizing enzymes(9)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

UGT2B7UDP-glucuronosyltransferase 2B7

substrate

UGT2B4UDP-glucuronosyltransferase 2B4

substrate

CYP2E1Cytochrome P450 2E1

substrate

CYP2A6Cytochrome P450 2A6

substrate

CYP2B6Cytochrome P450 2B6

substrate

inhibitor

inducer

CYP2C19Cytochrome P450 2C19

substrate

inhibitor

CYP3A4Cytochrome P450 3A4

substrate

inhibitor

inducer

CYP3A5Cytochrome P450 3A5

substrate

inhibitor

CYP2C8Cytochrome P450 2C8

inducer

Carriers(1)

Proteins that carry this drug through the body

Albumin

BE0000530

ALB

binder

Specific functionantioxidant activity

Cellular location

Secreted

General function & pharmacology

Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc .
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).

Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).

Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017

Scientific references(2)

Nakamura M., Cho J.H., Shin H., Jang I.S.

Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons.

European Journal Pharmacology

2019 Jul 15855:175-182. doi: 10.1016/j.ejphar.2019.05.007. Epub 2019 May 4

PMID: 31063770 DOI: 10.1016/j.ejphar.2019.05.007

Kasteleijn-Nolst Trenite D.G.A., DiVentura B.D., Pollard J.R., Krauss G.L., Mizne S., French J.A.

Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089).

Neurology

2019 Aug 693(6):e559-e567. doi: 10.1212/WNL.0000000000007894. Epub 2019 Jul 10

PMID: 31292226 DOI: 10.1212/WNL.0000000000007894

ATC classification(1 code)

ATC N03AX25

International brands(1)

Experimental properties(2)

Commercial products(59)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Cenobamate

DB06119

CAS number

913088-80-9

UNII (FDA)

P85X70RZWS

InChI Key (molecular fingerprint)

GFHAXPJGXSQLPT-VIFPVBQESA-N

Additional database identifiers

Drugs Product Database (DPD)

23860

ChemSpider

10136642

Wikipedia

Cenobamate

ChEMBL

CHEMBL3989949

RxCUI

2265690

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10585

GenAtlas

SCN1A

GeneCards

SCN1A

GenBank Gene Database

AF225985

GenBank Protein Database

12642270

IUPHAR

578

Guide to Pharmacology

578

UniProtKB

P35498

UniProt Accession

SCN1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10582

GenAtlas

SCN10A

GeneCards

SCN10A

GenBank Gene Database

AF117907

GenBank Protein Database

4838145

IUPHAR

585

Guide to Pharmacology

585

UniProtKB

Q9Y5Y9

UniProt Accession

SCNAA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10583

GenAtlas

SCN11A

GeneCards

SCN11A

GenBank Gene Database

AF188679

GenBank Protein Database

6572950

IUPHAR

586

UniProtKB

Q9UI33

UniProt Accession

SCNBA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10588

GenAtlas

SCN2A

GeneCards

SCN2A

GenBank Gene Database

M94055

GenBank Protein Database

457879

IUPHAR

579

Guide to Pharmacology

579

UniProtKB

Q99250

UniProt Accession

SCN2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10590

GenAtlas

SCN3A

GeneCards

SCN3A

GenBank Gene Database

AJ251507

GenBank Protein Database

7414320

IUPHAR

580

Guide to Pharmacology

580

UniProtKB

Q9NY46

UniProt Accession

SCN3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10591

GenAtlas

SCN4A

GeneCards

SCN4A

GenBank Gene Database

M81758

GenBank Protein Database

338213

IUPHAR

581

Guide to Pharmacology

581

UniProtKB

P35499

UniProt Accession

SCN4A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10593

GenAtlas

SCN5A

GeneCards

SCN5A

GenBank Gene Database

M77235

GenBank Protein Database

184039

IUPHAR

582

Guide to Pharmacology

582

UniProtKB

Q14524

UniProt Accession

SCN5A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10594

GeneCards

SCN7A

UniProtKB

Q01118

UniProt Accession

SCN7A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10596

GenAtlas

SCN8A

GeneCards

SCN8A

GenBank Gene Database

AF050736

GenBank Protein Database

4321647

IUPHAR

583

Guide to Pharmacology

583

UniProtKB

Q9UQD0

UniProt Accession

SCN8A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10597

GenAtlas

SCN9A

GeneCards

SCN9A

GenBank Gene Database

X82835

GenBank Protein Database

758110

IUPHAR

584

Guide to Pharmacology

584

UniProtKB

Q15858

UniProt Accession

SCN9A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4075

GenAtlas

GABRA1

GeneCards

GABRA1

GenBank Gene Database

X13584

GenBank Protein Database

31631

IUPHAR

404

Guide to Pharmacology

404

UniProtKB

P14867

UniProt Accession

GBRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12554

GeneCards

UGT2B7

GenBank Gene Database

J05428

GenBank Protein Database

340080

UniProtKB

P16662

UniProt Accession

UD2B7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12553

GeneCards

UGT2B4

GenBank Gene Database

Y00317

GenBank Protein Database

37589

UniProtKB

P06133

UniProt Accession

UD2B4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2631

GeneCards

CYP2E1

GenBank Gene Database

J02625

GenBank Protein Database

181360

Guide to Pharmacology

1330

UniProtKB

P05181

UniProt Accession

CP2E1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2610

GenAtlas

CYP2A6

GeneCards

CYP2A6

GenBank Gene Database

X13897

Guide to Pharmacology

1321

UniProtKB

P11509

UniProt Accession

CP2A6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2615

GeneCards

CYP2B6

GenBank Gene Database

M29874

GenBank Protein Database

181296

Guide to Pharmacology

1324

UniProtKB

P20813

UniProt Accession

CP2B6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2638

GenAtlas

CYP3A5

GeneCards

CYP3A5

GenBank Gene Database

J04813

GenBank Protein Database

181346

Guide to Pharmacology

1338

UniProtKB

P20815

UniProt Accession

CP3A5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2622

GenAtlas

CYP2C8

GeneCards

CYP2C8

GenBank Gene Database

M17397

Guide to Pharmacology

1325

UniProtKB

P10632

UniProt Accession

CP2C8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:399

GenAtlas

ALB

GeneCards

ALB

GenBank Gene Database

V00494

GenBank Protein Database

28590

UniProtKB

P02768

UniProt Accession

ALBU_HUMAN

Patent information

2 active patents

11654133

United States

Approved 23 May 2023 · Expires 16 Jun 2039

13y 2m

7598279

United States

Approved 6 Oct 2009 · Expires 30 Oct 2027

1y 7m

The earliest active patent expires October 2027. Generic versions may become available after this date.

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated about 1 month ago(4 Mar 2026)

Back to medicines

Cenobamate 200mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(2)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
12

Chemical identifiers

Cenobamate

Additional database identifiers

Patent information

DrugBank citations

Cenobamate 200mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(2)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science12

Chemical identifiers

Cenobamate

Additional database identifiers

Patent information

DrugBank citations

Deep science
12